Anticoagulants can reduce thrombotic risks in patients with myeloproliferative neoplasms. Key considerations include bleeding risks, kidney function, and drug interactions.

Anticoagulants help mitigate thrombosis in myeloproliferative cases but require monitoring for hemorrhage, assessing liver function, and adjusting doses accordingly.

In patients with myeloproliferative neoplasms, anticoagulants lower thrombotic risks. Careful patient selection and continuous monitoring for bleeding are crucial for safety.